Cyclosporine Oral, Intravenous and Gemifloxacin Mesylate

• Generic Name: cyclosporine
• Dosage Forms: n.a.
• Other Brand Names: Gengraf, Neoral, Sandimmune, Sandimmune

Cyclosporine injection is given together with a steroid medicine to prevent the body from rejecting a transplanted organ (e.g., kidney, liver, or heart). It belongs to a group of medicines known as immunosuppressive agents.

When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ. Cyclosporine works by suppressing the immune system to prevent the white blood cells from trying to get rid of the transplanted organ.

Cyclosporine is a very strong medicine. It can cause side effects that can be very serious, such as high blood pressure, kidney problems, or liver problems. It may also decrease the body's ability to fight infections. You and your doctor should talk about the benefits cyclosporine will do as well as the risks of using it.

Cyclosporine is to be given only by or under the direct supervision of a doctor.

• Generic Name: gemifloxacin
• Dosage Forms: n.a.
• Other Brand Names: Factive

Treatment of acute bacterial exacerbations of chronic bronchitis caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae, H. parainfluenzae, or Moraxella catarrhalis.

Treatment of mild to moderate community-acquired pneumonia (CAP) caused by susceptible S. pneumoniae (including multidrug-resistant strains; MDRSP), H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydophila pneumoniae (formerly Chlamydia pneumoniae), or Klebsiella pneumoniae.

Use for treatment of acute bacterial exacerbations of chronic bronchitis only when no other treatment options available. Because systemic fluoroquinolones, including gemifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that can occur together in the same patient (see Cautions) and because acute bacterial exacerbations of chronic bronchitis may be self-limiting in some patients, risks of serious adverse reactions outweigh benefits of fluoroquinolones for patients with these infections.